Acute Lymphoblastic Leukaemia Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about Acute Lymphoblastic Leukaemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Acute Lymphoblastic LeukaemiaHigher Risk Myelodysplastic SyndromesAcute Myeloid Leukaemia
AstraZeneca84 enrolled29 locationsNCT07155226
Recruiting

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

B-cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemia (B-ALL)+5 more
Arkansas Children's Hospital Research Institute300 enrolled2 locationsNCT07422337
Recruiting
Not Applicable

Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy

Acute Lymphoblastic Leukaemias (ALL)Long Term Follow-Up
University of Erlangen-Nürnberg Medical School30 enrolled1 locationNCT07313878
Recruiting

Blinatumomab Consolidation in Real World

B-Cell Acute Lymphoblastic Leukaemia
Medical College of Wisconsin200 enrolled1 locationNCT07117136
Recruiting
Phase 2

Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients

Philadelphia Chromosome Negative ALLAcute Lymphobkastic LeukemiaAcute Lymphoblastic Leukaemia Recurrent
Hospital Universitario Dr. Jose E. Gonzalez12 enrolled1 locationNCT07039877
Recruiting
Phase 1

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaAcute Lymphoblastic Leukaemia
CytoCares Inc44 enrolled1 locationNCT06037018
Recruiting
Phase 2Phase 3

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Relapsed B Acute Lymphoblastic LeukaemiaRefractory B Acute Lymphoblastic Leukaemia
National University of Malaysia10 enrolled1 locationNCT03937544
Recruiting
Phase 2

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial

Acute Myeloid LeukemiaChronic Myeloid LeukemiaMyelodysplastic Syndrome+3 more
Imperial College London50 enrolled8 locationsNCT06355583
Recruiting
Phase 2Phase 3

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukaemia
St. Anna Kinderkrebsforschung1,800 enrolled119 locationsNCT01949129